AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

Shares of AbbVie Inc. ABBV shed 2.74% to $164.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.32% to 5,870.62 and Dow ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie Inc. (ABBV) is a global biopharmaceutical company, founded in 2013 as a spinoff from Abbott Laboratories, focusing on discovering and delivering innovative medicines and solutions for complex ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

As of 2024-11-12, AbbVie Inc's intrinsic value as calculated by the Discounted Earnings model is $295.71. It's currently trading at a price of $174.43. Therefore, the margin of safety based on the ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...

AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...